Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2004

View Archived Issues

Antigenics highlights 2003 accomplishments

New tissue-selective androgen receptor agonists developed at Kaken

New p38 kinase inhibitors in early development at Celltech

Boehringer Ingelheim claims new urea-based p38 kinase inhibitors

Novel COX-2 inhibitors prepared and tested by Chinese team

Wyeth claims B7-1 inhibitors and their use in transplant rejection and autoimmune diseases

Astex presents two series of CDK2 inhibitors for cancer, fungal infections, etc.

Single dose of tyrosine kinase Syk inhibitor effective against allergic rhinitis

Pulmonary inflammatory diseases inhibition by novel lipoxin A4 and FPRL1 agonists

In vivo detection of pulmonary embolic thrombosis

Enhanced liver MRI using new macromolecular blood pool agent

New treatment guidelines for acute otitis media recommend Augmentin ES-600

U. of Missouri-Columbia Research Reactor Center to supply holmium-166 to NeoRx

Ono and Genetics Institute's research collaboration to end

Dade Behring grants Roche Diagnostics sublicense for hsCRP immunoassay

Transgenomic to manufacture components of regulatable anticoagulant therapy

Protein Design Labs reports clinical data for visilizumab and fontolizumab

Joint Netherlands project to focus on bone regeneration therapies

NeuroSearch obtains strategic ownership in PainCeptor Pharma

Positive pharmacokinetic results for new oral cladribine formulation

Phase I pharmacokinetic trial of orally dosed histamine completed

March 2004 meeting of European Committee for Orphan Medicinal Products

Tellurium compound, AS-101, is a potential treatment for alopecia

Alendronate efficacy maintained for a decade in postmenopausal women

CCI-779 demonstrates activity in renal cell carcinoma

Ecteinascidin-743 induces disease control in soft tissue sarcoma patients

Evidence supports the use of levetiracetam for phasic spasticity in multiple sclerosis